Key risks
- High valuation relative to earnings: PE of 30.01 versus ROE of 9.81% implies the market is pricing in growth not yet delivered in shareholder returns.
- Operational volatility: quarterly operating margins range from 6.44% to 20.96%, and one-year stock return is -5.53%, signaling cyclical or execution risk.
- China-plus-one positioning depends on sustained supply-chain fragmentation and policy continuity; verify if the company is winning share and whether gains are durable.
- Demand for intermediates and phenolics is cyclical; verify exposure to end-markets and downside resilience if pharma or industrial production slows.
Generated analysis · source review pending